A5055519116- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Renal and related cancers
- Childhood Cancer Survivors' Quality of Life
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- CRISPR and Genetic Engineering
- Nutrition, Genetics, and Disease
- Cancer-related Molecular Pathways
- DNA Repair Mechanisms
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Genetics, Bioinformatics, and Biomedical Research
- Genomic variations and chromosomal abnormalities
- Neuroblastoma Research and Treatments
- Colorectal and Anal Carcinomas
- Ethics and Legal Issues in Pediatric Healthcare
- Cancer-related gene regulation
- Prenatal Screening and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Chromatin Remodeling and Cancer
- Sarcoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
The University of Texas Health Science Center at San Antonio
2015-2025
Université Bourgogne Franche-Comté
2025
The University of Texas Health Science Center at Houston
2011-2024
Mays Cancer Center at UT Health San Antonio
2020-2024
The University of Texas Southwestern Medical Center
2006-2023
Children's Cancer Center
2012-2023
The University of Texas at San Antonio
2022
University of Toronto
2009-2020
Public Health Ontario
2019
Palmetto Hematology Oncology
2016
Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks breast ovarian cancer.To estimate risk mortality reduction stratified mutation prior cancer status.Prospective, multicenter cohort study 2482 women with ascertained between 1974 2008. The was conducted at 22 clinical research genetics centers in Europe North America assess the relationship risk-reducing mastectomy outcomes. were followed up until end 2009.Breast risk,...
To determine if tumor-specific loss of heterozygosity (LOH) for chromosomes 1p or 16q is associated with a poorer prognosis children favorable-histology (FH) Wilms tumor entered on the fifth National Tumor Study (NWTS-5).Between August 1995 and June 2002, 2,021 previously untreated FH anaplastic tumor, clear-cell sarcoma kidney (CCSK) malignant rhabdoid (RTK), were treated stage- histology-specific therapy. Their tumors assayed LOH polymorphic DNA markers 16q. ResultsLOH was rarely observed...
Purpose Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal choose to take hormone replacement therapy (HRT) after undergoing BPO abrogate immediate symptoms of surgically-induced menopause. Thus, we evaluated whether the breast conferred by mutation carriers altered use post-BPO HRT. Methods We identified a prospective cohort 462 disease-associated germline mutations at 13 medical centers evaluate and without...
Purpose: To prospectively determine cancer yield, callback and biopsy rates, positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, ultrasonography (US) in women at high risk for breast cancer. Materials Methods: The study was approved by the institutional review board HIPAA compliant, informed consent obtained. We conducted a prospective pilot screening MR, US asymptomatic 25 years age or older who were genetically risk, defined as BRCA1/BRCA2 carriers with least...
An accurate evaluation of the penetrance BRCA1 and BRCA2 mutations is essential to identification clinical management families at high risk breast ovarian cancer. Existing studies have focused on Ashkenazi Jews (AJ) or from outside United States. In this article, we consider US population using largest US-based cohort date both AJ non-AJ families.We collected 676 1,272 other ethnicities through Cancer Genetics Network. Two hundred eighty-two were based, whereas remainder was counseling...
Despite being the most common liver cancer in children, hepatoblastoma (HB) is a rare neoplasm. Consequently, few pretreatment tumors have been molecularly profiled, and there are no validated prognostic or therapeutic biomarkers for HB patients. We report on first large-scale effort to profile HBs at diagnosis. Our analysis of 88 clinically annotated revealed three risk-stratifying molecular subtypes that characterized by differential activation hepatic progenitor cell markers metabolic...
Cancer is a leading cause of death in the United States and across globe. screening an effective preventive measure that can reduce cancer incidence mortality. While integral to control prevention, due COVID-19 outbreak many screenings have either been canceled or postponed, leaving vast number patients without access recommended health care services. This disruption services may significant impact on patients, practitioners, systems. In this paper, we aim offer comprehensive view screening....
The goal of our study was to develop a panel tumor cell lines along with paired non-malignant or strains collected from breast cancers, predominantly primary tumors. From total 189 samples consisting 177 tumors and 12 metastatic tissues, we established 21 human that included 18 derived 3 lesions. Cell those patients germline BRCA1 FHIT gene mutations others possible genetic predisposition. For 19 lines, also one more corresponding B lymphoblastoid (BL) which 16 BL 7 epithelial (2) stromal...
The objective of this study is to determine prognostic factors in rhabdoid tumor the kidney (RTK), including both demographic and treatment variables.A total 142 patients studied on National Wilms' Tumor Studies 1, 2, 3, 4, 5 were analyzed. Patients enrolled between years 1969 2002. Variables examined included sex, age diagnosis, stage, presence CNS lesions, as well variables, use doxorubicin and/or radiotherapy (RT).No survival differences observed males females, those treated with or...
Mutations in BRCA1 are responsible for nearly all of the hereditary ovarian and breast cancers, about half those cancer-only kindreds. The ability to transactivate p21 promoter can be inactivated by mutation conserved C-terminal (BRCT) repeats. To explore mechanisms this function, BRCT repeats were used as bait a yeast two-hybrid screen. A known protein, CtIP, co-repressor with CtBP, was found. CtIP interacts specifically BRCA1, bothin vitro vivo, tumor-derived mutations region abolished...